M 6620

Drug Profile

M 6620

Alternative Names: Captisol® enabled VX 970; M6620; VX-970

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck KGaA; National Cancer Institute (USA)
  • Class Antineoplastics
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II Small cell lung cancer; Solid tumours
  • Phase I Breast cancer
  • Preclinical Acute myeloid leukaemia
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top